{"database": "press", "table": "releases", "rows": [["https://buchanan.house.gov/2022/10/meritact", "Buchanan Introduces Bill to Improve Access to New Drugs and Treatments for Seniors", "2022-10-04", "2022", "2022-10", "Republican", "House", "FL", "Vern Buchanan", "B001260", "buchanan.house.gov", "buchanan", "https://buchanan.house.gov/press-releases", "scraper", "WASHINGTON \u2013 Congressman Vern Buchanan today announced that he has introduced legislation to help ensure coverage of potentially life-saving drugs and new treatments for Medicare beneficiaries.\n\nIn an unprecedented move, earlier this year unelected bureaucrats at the Centers for Medicare and Medicaid Services (CMS) unilaterally restricted coverage for the first new treatment for Alzheimer\u2019s disease (Aduhelm) in nearly two decades, despite prior approval from scientists at the Food and Drug Administration (FDA). In doing so, CMS cast a very wide net by restricting coverage of any similar drugs in its class.\n\n\u201cThe federal government should make it easier for seniors to access breakthrough treatments, not unreasonably restrict potentially life-changing drugs for our nation\u2019s most vulnerable patients,\u201d said Buchanan. \u201cUnfortunately, the Biden administration and Democrats in Washington have continuously pursued policies that will stifle innovation, halt progress toward revolutionary cures and move manufacturing overseas \u2013 particularly to China.\u201d\n\nTo protect similar drugs from future bureaucratic overreach, Buchanan\u2019s Mandating Exclusive Review of Individual Treatments (MERIT) Act requires the CMS to evaluate treatments and cures individually and based on their own merits, rather than as a broad class of drugs.\n\nBuchanan introduced this legislation with Congresswoman Nanette Barrag\u00e1n (D-Ca.) and penned an op-ed in the Bradenton Herald on CMS\u2019s restriction of Aduhelm earlier this year.\n\nBy requiring CMS to review each drug individually, the MERIT Act will undo the actions taken by CMS that would otherwise unnecessarily limit access to drugs like Aduhelm for seniors. With additional drugs to treat Alzheimer\u2019s preparing to come to market soon, this bill will ensure those drugs receive fair and accurate consideration for coverage, rather than requiring onerous additional steps before CMS will make them available to Medicare beneficiaries. For example, just this week, preliminary data for a second drug to treat Alzheimer\u2019s in the same way as Aduhelm was released and showed promise in slowing the progression of this horrible disease.\n\nBuchanan\u2019s bill is supported by the Alzheimer\u2019s Association, UsAgainstAlzheimer\u2019s and the Global Alzheimer\u2019s Platform Foundation.\n\nRobert Egge, Alzheimer\u2019s Association chief public policy officer and Alzheimer\u2019s Impact Movement (AIM) executive director said, \u201cNo two treatments are the same, even if they are in the same class of drug, and CMS should not determine coverage based on type of treatment. Thank you to Representatives Buchanan and Barragan for introducing this critical, bipartisan legislation and supporting people living with Alzheimer\u2019s and all other dementia.\u201d\n\nGeorge Vradenburg, chair and co-founder of UsAgainstAlzheimer\u2019s, said, \u201cThis bill corrects a massive injustice by CMS against people with Alzheimer\u2019s. The decision by CMS to deny coverage for the first class of disease-modifying Alzheimer\u2019s treatments, including those still in clinical trials, was cruel and unconscionable. Further, for the first time in history, CMS refused to cover an FDA-approved drug, discriminating against millions of people living with this disease. This bill will help ensure CMS reviews each drug based on its own merits and prevent the agency from making uninformed blanket coverage decisions in the future.\u201d\n\nJohn Dwyer, president of the Global Alzheimer\u2019s Platform Foundation said, \u201cWe strongly support Congressman Buchanan's proposed changes to Medicare's NCD process. The changes are needed to avoid unwarranted bureaucratic delays and ensure access to new therapies for patients with Alzheimer's or other life-threatening diseases.\u201d\n\nSimilarly, the FDA just approved a new drug to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig\u2019s disease, the third drug available to treat ALS symptoms available in the United States. Without legislation like the MERIT Act requiring consideration of each drug on its own merits, CMS could implement another overly restrictive decision for any new ALS drugs based on just this one, which would inhibit access to new treatments for the nearly 30,000 ALS patients across America.\n\nIn addition to being second in seniority on the Ways and Means Committee after Leader Kevin Brady, Buchanan is the lead Republican on the Health Subcommittee. He also co-chairs the 17-member Republican Healthy Future Task Force, which was created to develop solutions to modernize the American health care system to lower costs, keep Americans healthy, develop better therapies and cures and provide Americans with more choices.", 1, "2026-03-30T01:40:41Z", "2026-04-08T03:20:33Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://buchanan.house.gov/2022/10/meritact"], "units": {}, "query_ms": 1.7295810393989086, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}